Asian Spine J.  2016 Jun;10(3):553-557. 10.4184/asj.2016.10.3.553.

Denosumab for Treatment of a Recurrent Cervical Giant-Cell Tumor

Affiliations
  • 1Department of Orthopedic Surgery, Chiba Cancer Center, Chiba, Japan. kamodahiroto@gmail.com
  • 2Department of Orthopedic Surgery, Chiba University, Chiba, Japan.
  • 3Department of Orthopedic Surgery, Tsukuba University, Ibaraki, Japan.
  • 4Department of Orthopedic Surgery, National Hospital Organization Chiba Medical Center, Chiba, Japan.

Abstract

A 43-year-old male patient with C5 giant cell tumor (GCT) underwent tumor resection and anterior bone fusion of C4-C6. The tumor recurred locally 9 months after surgery with the patient complaining of neck and shoulder pain similar to his preoperative symptoms. Denosumab was administered and his pain disappeared after a two-month administration, with a sclerotic rim formation seen at the tumor site on computed tomography. He has been followed for 18 months with no evidence of tumor recurrence. Complete resection is generally recommended, but is not easy for many patients with cervical GCT because of the existence of neurovascular structures. Some patients suffer from recurrence and treatment becomes more difficult. As such, denosumab may be an efficacious option for treatment of recurrent GCT of the cervical spine, although long-term follow-up is required to monitor for presence or absence of recurrence.

Keyword

Cervical vertebrae; Giant cell tumor of bone; Recurrence; Denosumab

MeSH Terms

Adult
Cervical Vertebrae
Denosumab*
Female
Follow-Up Studies
Giant Cell Tumor of Bone
Giant Cell Tumors
Humans
Male
Neck
Recurrence
Shoulder Pain
Spine
Denosumab
Full Text Links
  • ASJ
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr